Answers are grounded in this paper and cite their sources.
nonhematopoietic and hematopoietic cells indicated no off-target toxicity. Therefore, administration of BOB1-specific TCR-engineered T cells may provide novel cellular treatment options to patients with B-cell malignancies, including multiple myeloma.
No takes yet. Share an insight, caveat, or question.
Jahn et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: